Chinese pharmaceutical company
Appears in 2 stories
Licensor of AVR-001 and co-lead investor in the financing
The team that built Akero Therapeutics and sold it to Novo Nordisk for up to $5.2 billion has a second act. On Tuesday, their new startup, Avere Therapeutics, agreed to merge with struggling public biotech NextCure and raised $320 million to fund it.
Updated Yesterday
Developer of HS-20093, the lead B7-H3 ADC in China
Patients with advanced esophageal squamous cell carcinoma who fail both chemotherapy and immunotherapy have almost no good options. On May 11, China's drug regulator granted breakthrough status to Hansoh Pharmaceutical's HS-20093, a targeted cancer drug built around a protein called B7-H3.
Updated May 11
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
